The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Chimeric antigen receptor (CAR) T-cell therapy is rapidly evolving and changing the treatment landscape of multiple myeloma (MM). Therefore the MM Hub is featuring January’s educational theme based on the topic. One of the targets of CAR T therapies is plasma cell surface molecule BCMA (B-cell maturation antigen). You can read more about the anti-BCMA T-cell therapies here. bb21217, an investigational anti-BCMA CAR T cell therapy, uses the idecabtagene vicleucel (ide-cel; bb2121) CAR molecule and is cultured with the PI3 kinase inhibitor (bb007).
CRB-402 (NCT03274219) is a first-in-human, phase I clinical trial investigating safety, pharmacokinetics, and efficacy of bb21217 in patients with R/R MM. The MM Hub has previously covered the initial results of the ongoing trial. During the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, US, Jesus G. Berdeja, Sarah Cannon Center for Blood Cancers, Nashville, US, presented updated results from the trial.1 Here we provide a summary of this oral presentation.*
Table 1. Baseline patient characteristics
ECOG PS, The Eastern Cooperative Oncology Group performance status; IMiD, immunomodulatory imide drug; ISS, International Staging System; SCT, stem cell transplantation |
|
Characteristics |
Patients (N= 38) |
---|---|
Median (min, max) age, years |
62 (33, 74) |
Male, n (%) |
21 (55) |
Median (min, max) time since initial diagnosis, years |
5.5 (1.0, 13.5) |
ECOG PS, n (%) 0 1 2 |
12 (32) 24 (63) 2 (5) |
ISS stage, n (%) I II III Unavailable |
11 (29) 7 (18) 10 (26) 10 (26) |
High-risk cytogenetics, n (%) Del(17p), t(4;14), t(14;16) Unknown |
13 (34) 1 (3) |
Median (min, max) number prior regimens |
6 (3, 7) |
Prior autologous SCT, n (%) 0 1 >1 |
7 (18) 22 (58) 9 (24) |
Prior therapies, n (%), exposed/refractory IMiD agent Proteosome inhibitor Anti-CD38 antibody Cumulative PI/IMiD/Anti-CD38 |
38 (100)/ 30 (79) 38 (100)/ 33 (89) 36 (95)/ 29 (76) 36 (95)/ 24 (63) |
Table 2. Grade 3/4 treatment-emergent AEs (TEAEs) in >2 patients
TEAE, treatment-emergent adverse event |
|
TEAE, n (%) |
Grade 3/4 (N=38) |
---|---|
Neutropenia |
31 (82) |
Leukopenia |
21 (55) |
Thrombocytopenia |
21 (55) |
Anemia |
19 (50) |
Lymphopenia |
13 (34) |
Hypophosphatemia |
8 (21) |
Infections |
7 (18) |
Hyponatremia |
5 (13) |
Febrile neutropenia |
4 (11) |
Table 3. Summary of cytokine release syndrome (CRS) and neurotoxicity events
|
N |
Grade, n (%) |
Total |
||
---|---|---|---|---|---|
3 |
4 |
5 |
|||
CRS |
|||||
Total 150 x 106 300 x 106 450 x 106 |
38 12 14 12 |
1 (3) 1 (8) 0 0 |
0 0 0 0 |
1 (3) 0 0 1 (8) |
25 (66) 8 (67) 7 (50) 10 (83) |
Neurotoxicity |
|||||
Total 150 x 106 300 x 106 450 x 106 |
38 12 14 12 |
2 (5) 0 1 (7) 1 (8) |
1 (3) 1 (8) 0 0 |
0 0 0 0 |
9 (24) 3 (25) 4 (29) 2 (17) |
CRS, cytokine release syndrome |
Table 4. Responses to bb21217 and measurable residual disease (MRD) status
aMRD negativity defined as < 10-5 tumor plasma cells; CR, complete response; PD, progressive disease; PR, partial response; sCR, stringent complete response; VGPR, very good partial response |
|||
Response |
CAR+ T cells |
||
---|---|---|---|
150 x 106 |
300 x 106 |
450 x 106 |
|
Median follow-up (range), months |
17.6 (12–23) |
4.0 (2 –10) |
3.3 (< 1–6) |
Confirmed response, n (%) sCR/CR VGPR PR Total |
4 (33) 6 (50) 0 10 (83) |
0 4 (29) 2 (14) 6 (43) |
1 (14) 2 (29) 1 (14) 4 (57) |
Median time to 1st response (range), months |
1.0 (1.0–1.9) |
1.0 (1.0–1.0) |
1.0 (1.0–1.8) |
MRD status in bone marrow Evaluable responders, n MRD negativea, n |
7 7 |
6 5 |
4 4 |
The presented data demonstrate the safety profile of bb21217 as consistent with known CAR T-cell products and show promising efficacy in patients with R/R MM. The expansion part of the study is ongoing to confirm the dose recommended for phase II study.
*The article is based on the data presented at the ASH meeting and may supersede the data in the published abstract.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content